Rehabilitation of a large radicular cyst of the mandible without using any bone substitutes: Case report

The radicular cyst variously known as periapical, apical periodontal, dentoalveolar or rootend cyst is an inflammatory jaw cyst at the apices of teeth with infected and necrotic pulps. A radicular cyst arises from the epithelial residues in the periodontal ligament as a result of inflammation, usually following death of the pulp. Radicular cysts are the most common odontogenic cystic lesions of inflammatory origin and are managed either by surgical enucleation or by marsupialization. We illustrate the possibility of complete healing of a cystic periapical lesion of huge proportion in permanent dentition of a 58 year-old male patient under general anesthesia with conservation of vital structures and without using any bone substitute

A misdiagnosed keratoacanthoma turned out to be a metastatic parotid carcinoma

Distinguishing keratoacanthoma from well-differentiated squamous-cell carcinoma is often difficult on account of the clinical and histopathological similarities between them. Since the outcome of treatment depends on identifying the correct diagnosis and having the correct treatment on time, it is essential to differentiate keratoacanthoma and squamous-cell carcinoma as soon and accurately as possible. A paradigmatic case is herein reported. An 85 year-old female underwent total parotidectomy and ipsilateral neck dissection due to the squamous-cell carcinoma of the parotid gland. The investigations, in order to determine whether the tumour was a metastatic or a primary one, led to a misdiagnosis. A prior skin lesion, which was excised over her left cheek one year ago in another clinic, was diagnosed as keratoacanthoma. However, the histopathological revision of the specimen revealed that the lesion was in fact a squamous-cell carcinoma. Thus the parotid tumour was accepted as metastatic squamous-cell carcinoma rather than primary squamous-cell carcinoma

The effect of garlic derivatives (S-allylmercaptocysteine, diallyl disulfide, and S-allylcysteine) on gentamicin induced ototoxicity: An experimental study

Objectives Gentamicin is a potent aminoglycoside antibiotic. Ototoxicity and nephrotoxicity are the main side effects which restrict the use of gentamicin. Garlic with its intrinsic antioxidant activity may prove beneficial in prevention from ototoxicity. S-allylmercaptocysteine (SAMC), diallyl disulfide (DD), and S-allylcysteine (SAC) are three active compounds found in garlic. In this study, we investigated the effect of SAMC, DD, and SAC on the ototoxicity induced by gentamicin in rats, by using brainstem evoked response audiometry (BERA). Methods Thirty male Wistar rats with intact Preyer’s reflex initially weighing 220–260 g were randomly assigned to either the gentamicin injection with SAMC treatment group (Genta-w SAMC), DD treatment group (Genta-w DD), SAC treatment group (Genta-w SAC), gentamicin injection without any active compounds (AC) treatment groups (Genta-w/o AC), or control group (n=6 rats each group). Gentamicin was given 120-mg/kg body weight, intraperitoneally once daily for 25 days to subjects in all groups except the control group. SAMC 100-mg/kg, and DD 50-mg/kg body weight were given intragastrically, and SAC 250-mg/kg body weight was given intraperitoneally once daily to subjects in Genta-w SAMC, and Genta-w DD, and Genta-w SAC groups, respectively during the study. After 25 days hearing thresholds were evaluated by using BERA test. Results The mean amplitude of auditory thresholds (sensation level [SL]) measured by using BERA for the Genta-w SAMC, Genta-w DD, Genta-w SAC, Genta-w/o AC, and control groups were 22±8, 25±5, 30±9, 54±11, and 10±7 dB SL, respectively (mean±SD). The differences between every active compound group (Genta-w SAMC, Genta-w DD, and Genta-w SAC) and Genta-w/o AC were statistically significant (P<0.016). Conclusion SAMC, DD, and SAC are derivative of garlic seems to attenuate aminoglycoside-induced hearing loss. The effect of SAMC and DD seems to be more prominent than that of SAC

A misdiagnosed keratoacanthoma turned out to be a metastatic parotid carcinoma [Erronea diagnosi di keratoacantoma in un caso di metastasi parotidea da carcinoma squamoso]

Distinguishing keratoacanthoma from well-differentiated squamous-cell carcinoma is often difficult on account of the clinical and histopathological similarities between them. Since the outcome of treatment depends on identifying the correct diagnosis and having the correct treatment on time, it is essential to differentiate keratoacanthoma and squamous-cell carcinoma as soon and accurately as possible. A paradigmatic case is herein reported. An 85 year-old female underwent total parotidectomy and ipsilateral neck dissection due to the squamous-cell carcinoma of the parotid gland. The investigations, in order to determine whether the tumour was a metastatic or a primary one, led to a misdiagnosis. A prior skin lesion, which was excised over her left cheek one year ago in another clinic, was diagnosed as keratoacanthoma. However, the histopathological revision of the specimen revealed that the lesion was in fact a squamous-cell carcinoma. Thus the parotid tumour was accepted as metastatic squamous-cell carcinoma rather than primary squamous-cell carcinoma

The Effect of Garlic Derivatives (S-Allylmercaptocysteine, Diallyl Disulfide, and S-Allylcysteine) on Gentamicin Induced Ototoxicity: An Experimental Study

Objectives. Gentamicin is a potent aminoglycoside antibiotic. Ototoxicity and nephrotoxicity are the main side effects which restrict the use of gentamicin. Garlic with its intrinsic antioxidant activity may prove beneficial in prevention from ototoxicity. S-allylmercaptocysteine (SAMC), diallyl disulfide (DD), and S-allylcysteine (SAC) are three active compounds found in garlic. In this study, we investigated the effect of SAMC, DD, and SAC on the ototoxicity induced by gentamicin in rats, by using brainstem evoked response audiometry (BERA). Methods. Thirty male Wistar rats with intact Preyer's reflex initially weighing 220-260 g were randomly assigned to either the gentamicin injection with SAMC treatment group (Genta-w SAMC), DD treatment group (Genta-w DD), SAC treatment group (Genta-w SAC), gentamicin injection without any active compounds (AC) treatment groups (Genta-w/o AC), or control group (n=6 rats each group). Gentamicin was given 120-mg/kg body weight, intraperitoneally once daily for 25 days to subjects in all groups except the control group. SAMC 100-mg/kg, and DD 50-mg/kg body weight were given intragastrically, and SAC 250-mg/kg body weight was given intraperitoneally once daily to subjects in Genta-w SAMC, and Genta-w DD, and Genta-w SAC groups, respectively during the study. After 25 days hearing thresholds were evaluated by using BERA test. Results. The mean amplitude of auditory thresholds (sensation level {[}SL]) measured by using BERA for the Genta-w SAMC, Genta-w DD, Genta-w SAC, Genta-w/o AC, and control groups were 22 +/- 8, 25 +/- 5, 30 +/- 9, 54 +/- 11, and 10 +/- 7 dB SL, respectively (mean +/- SD). The differences between every active compound group (Genta-w SAMC, Genta-w DD, and Genta-w SAC) and Genta-w/o AC were statistically significant (P < 0.016). Conclusion. SAMC, DD, and SAC are derivative of garlic seems to attenuate aminoglycoside-induced hearing loss. The effect of SAMC and DD seems to be more prominent than that of SAC

Nilotinib Results in Improved Rates of Molecular Response in Turkish Newly Diagnosed CML-CP Patients: A 24-Month Update

WOS: 00034924270121

Frontline Nilotinib Treatment In Turkish Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia In Chronic Phase: Updated Results With 2 Years Of Follow-Up

Objectives: This report presents final results (24 months of follow-up) from the first prospective, national study of frontline nilotinib in chronic myeloid leukemia (CML) patients in Turkey. Methods: Patients with newly diagnosed Philadelphia chromosome-positive CML in chronic phase (CML-CP; N = 112) received nilotinib 300 mg twice daily. The primary endpoint, which was the cumulative rate of major molecular response (MMR; BCR-ABL1 <= 0.1% on the International Scale [BCR-ABL1(IS)]) by 12 months, was previously reported (66.1% [80% CI, 59.7%-72.0%]). ClinicalTrials.gov identifier NCT01274351 Results: By 24 months, 83.0% of patients achieved MMR, and 50.9% achieved MR4.5 (BCR-ABL1(IS) <= 0.0032%). Safety results at 24 months were consistent with those at 12 months. No additional deaths or disease progressions to accelerated phase/blast crisis were observed between 12 and 24 months. Discussion: Treatment with nilotinib 300 mg twice daily for 2 years provided high MMR with a good safety/tolerability profile in newly diagnosed CML-CP patients in Turkey. Assessment of MMR across time points showed increasing rates through 18 months, after which as lower rate of increase was observed. The safety profile of nilotinib 300 mg twice daily with 24 months of follow-up was similar to that observed at 12 months, and no new safety concerns were identified. These efficacy and safety findings are consistent with the results from the 12-month analysis of this study and from previous nilotinib studies. These findings support nilotinib as an option for frontline treatment of CML-CP. Conclusion: Frontline nilotinib treatment provided sustained efficacy, with good tolerability, over 24 months in newly diagnosed CML-CP patients.WoSScopu